Osterweis Capital Management Inc. Has $10.66 Million Stock Position in Natera, Inc. (NASDAQ:NTRA)

Osterweis Capital Management Inc. cut its holdings in Natera, Inc. (NASDAQ:NTRA) by 11.3% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 67,315 shares of the medical research company’s stock after selling 8,595 shares during the period. Osterweis Capital Management Inc.’s holdings in Natera were worth $10,656,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of NTRA. Wilmington Savings Fund Society FSB acquired a new position in shares of Natera during the 3rd quarter worth approximately $385,000. Everence Capital Management Inc. acquired a new stake in Natera during the fourth quarter worth approximately $573,000. Smartleaf Asset Management LLC grew its position in Natera by 50.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 657 shares of the medical research company’s stock worth $104,000 after buying an additional 220 shares in the last quarter. SeaBridge Investment Advisors LLC bought a new position in Natera during the 4th quarter worth $2,894,000. Finally, SYM FINANCIAL Corp acquired a new position in Natera in the 4th quarter valued at $256,000. 99.90% of the stock is owned by institutional investors.

Natera Trading Down 1.0 %

Shares of NASDAQ NTRA opened at $150.17 on Thursday. The stock has a market cap of $20.30 billion, a P/E ratio of -85.32 and a beta of 1.80. The firm has a 50 day moving average price of $151.17 and a two-hundred day moving average price of $152.38. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. Natera, Inc. has a 52-week low of $83.13 and a 52-week high of $183.00.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.01. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business had revenue of $476.10 million during the quarter, compared to analyst estimates of $447.91 million. As a group, equities analysts forecast that Natera, Inc. will post -1.49 EPS for the current year.

Insider Transactions at Natera

In other news, insider Solomon Moshkevich sold 24,861 shares of the business’s stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total value of $4,101,319.17. Following the transaction, the insider now directly owns 140,684 shares of the company’s stock, valued at $23,208,639.48. The trade was a 15.02 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Steven Leonard Chapman sold 78,553 shares of Natera stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total value of $12,958,888.41. Following the completion of the sale, the chief executive officer now owns 267,629 shares of the company’s stock, valued at approximately $44,150,756.13. The trade was a 22.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 325,922 shares of company stock worth $51,603,664 over the last ninety days. 7.60% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on NTRA. Royal Bank of Canada initiated coverage on Natera in a research report on Thursday, March 13th. They issued an “outperform” rating and a $251.00 price target on the stock. Guggenheim boosted their price objective on shares of Natera from $170.00 to $200.00 and gave the company a “buy” rating in a research report on Friday, January 17th. Barclays cut their target price on Natera from $200.00 to $160.00 and set an “overweight” rating for the company in a research note on Thursday, April 10th. Robert W. Baird boosted their price target on Natera from $183.00 to $188.00 and gave the stock an “outperform” rating in a report on Friday, February 28th. Finally, The Goldman Sachs Group raised their price objective on Natera from $160.00 to $190.00 and gave the company a “buy” rating in a research note on Tuesday, January 28th. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Natera currently has an average rating of “Moderate Buy” and an average price target of $175.76.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.